Novavax (NVAX) Enterprise Value (2010 - 2026)
Novavax (NVAX) posted quarterly Enterprise Value of -$790.3 million for Q1 2026, down 65.07% year-over-year from -$2.3 billion in Q1 2025, and down 56.4% quarter-over-quarter from -$505.3 million in Q4 2025.
Novavax (NVAX) Enterprise Value (2010 - 2026) Analysis & Trends
Novavax's Enterprise Value history runs 17 years deep, the most recent figure standing at -$790.3 million for Q1 2026.
- In Q1 2026, Enterprise Value fell 65.07% year-over-year to -$790.3 million; the TTM figure through Mar 2026 stood at -$790.3 million (down 65.07% YoY), while the FY2025 annual figure was -$505.3 million, down 25.23% from the prior year.
- Enterprise Value for Q1 2026 stood at -$790.3 million, down from -$505.3 million in the prior quarter.
- The five-year high for Enterprise Value was -$10.3 million in Q2 2022, with the low at -$1.6 billion in Q1 2022.
- The 5-year median for Enterprise Value is -$505.9 million (2023), against an average of -$545.6 million.
- The sharpest annual moves came in 2022 and 2023: Enterprise Value jumped 99.5% in 2022, then slumped 5937.13% in 2023.
- Novavax's Enterprise Value stood at -$10.3 million in 2022, then tumbled by 5417.86% to -$568.5 million in 2023, then climbed by 29.02% to -$403.5 million in 2024, then declined by 25.23% to -$505.3 million in 2025, then tumbled by 56.4% to -$790.3 million in 2026.
- Business Quant data shows NVAX's Enterprise Value at -$790.3 million in Q1 2026, -$505.3 million in Q4 2025, and -$762.9 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Enterprise Value (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | -7.85 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | -7.99 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | -5.18 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | -3.94 Bn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | -5.10 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | -8.46 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 2.12 Bn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | -3.31 Bn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | -1.16 Bn |
| 10 | Novavax | 1.33 Bn | 607.37 Mn | 42.45 Mn | -719.40 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -719.40 Mn |
| Mar 31, 2026 | -790.33 Mn |
| Dec 31, 2025 | -505.33 Mn |
| Sep 30, 2025 | -762.87 Mn |
| Jun 30, 2025 | -612.26 Mn |
| Mar 31, 2025 | -478.78 Mn |
| Dec 31, 2024 | -403.51 Mn |
| Sep 30, 2024 | -909.50 Mn |
| Jun 30, 2024 | -379.92 Mn |
| Mar 31, 2024 | -480.59 Mn |
| Dec 31, 2023 | -568.51 Mn |
| Sep 30, 2023 | -651.10 Mn |
| Jun 30, 2023 | -505.91 Mn |
| Mar 31, 2023 | -624.95 Mn |
| Dec 31, 2022 | -10.30 Mn |
| Sep 30, 2022 | -10.79 Mn |
| Jun 30, 2022 | -10.27 Mn |
| Mar 31, 2022 | -1.57 Bn |
| Dec 31, 2021 | -11.49 Mn |
| Sep 30, 2021 | -1.94 Bn |